Seroprevalence of SARS-CoV-2 –specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data

Coronavirus disease in 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a global pandemic1. COVID-19 was first reported in Wuhan, China, in December 2019, among a group of individuals presenting with atypical pneumonia of unknown etiology2. Published data suggests that patients with a history of or active malignancy are at increased risk of infection and developing COVID-19 related complications3,4. Data from China have shown that cancer patients infected with COVID-19 are at 3.5 times the risk of requiring mechanical ventilation or intensive care unit (ICU) admission, compared to the general population3.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Hot Topic Source Type: research